0001818382 false 0001818382 2021-08-27 2021-08-27 0001818382 us-gaap:CommonStockMember 2021-08-27 2021-08-27 0001818382 HUMA:RedeemableWarrantsEachWholeWarrantExercisableForOneOfCommonAtExercisePriceOf11.50Member 2021-08-27 2021-08-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 27, 2021

 

HUMACYTE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-39532   85-1763759
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification No.)

 

2525 East North Carolina Highway 54

Durham, North Carolina

  27713
(Address of principal executive offices)   (Zip Code)

 

(919) 313-9633

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbols   Name of each exchange on which
registered
Common Stock, par value $0.0001 per share   HUMA   The Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50   HUMAW   The Nasdaq Stock Market LLC

 

x Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

As previously announced, on August 26, 2021, Humacyte, Inc. (formerly known as Alpha Healthcare Acquisition Corp.) (the “Company”), Humacyte Global, Inc. (“Legacy Humacyte”) and Hunter Merger Sub, Inc. (“Merger Sub”) consummated a business combination (the “Business Combination”) in connection with which Merger Sub merged with and into Legacy Humacyte, with Legacy Humacyte surviving as a wholly owned subsidiary of the Company. In 2021, the Company awarded bonuses to two of its named executive officers for individual performance during 2020 that were payable upon the closing of the Business Combination: (i) Mr. Jeff Lawson, the Company’s Chief Surgical Officer, was granted a bonus in the amount of $87,524; and (ii) Ms. Heather Prichard, the Company’s Chief Operating Officer, was granted a bonus in the amount of $54,000. The Company also increased Ms. Prichard’s annual base salary to $370,800 for the fiscal year ended December 31, 2021.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: September 2, 2021

 

HUMACYTE, INC.  
     
By: /s/ Dale Sander  
Name: Dale Sander  
Title: Chief Financial Officer  


3